摘要
目的探析在多发性骨髓瘤骨病的治疗中采用两种不同剂量硼替佐米联合伊班膦酸的治疗效果。方法随机选取2014年11月—2016年11月于淄博市中心医院接受治疗的90例多发性骨髓瘤骨病患者进行分析,并均分为对照组与观察组;两组患者均予以伊班膦酸进行治疗,其中对照组在此基础上联用常规剂量的硼替佐米,观察组在此基础之上联用低剂量硼替佐米。对比分析两组患者的不良反应发生情况。结果对照组的不良反应发生率(22.22%)高于观察组(6.67%),其比较间存在的差异有统计学意义(P<0.05)。结论对于多发性骨髓瘤骨病患者而言,在伊班膦酸的治疗基础上联合常规剂量与低剂量的硼替佐米在病情控制、临床效果上基本相差不大,但是低剂量的硼替佐米在安全性上较为可观,因而更值得临床推广。
Objective To discuss the effect of two doses of bortezomib and ibandronic acid in treatment of multiple myeloma. Methods 90 cases of patients with multiple myeloma treated in our hospital from November 2014 to November 2016 were randomly selected and divided into two groups, both groups were treated with ibandronic acid, the control group adopted the routine –dose bortezomib on this basis, while the observation group adopted the low-dose bortezomib on this basis,and the occurrence of adverse reactions were compared between the two groups. Results The incidence rate of adverse reactions in the control group was higher than that in the observation group（22.22% vs 6.67%）, and the difference was statistically significant（P〈0.05）. Conclusion The difference in the clinical effect of routine-dose and low-dose bortezomib on the basis of the ibandronic acid for patients with multiple myeloma is not big, but the safety of low-dose bortezomib is obvious,therefore, it is worth clinical promotion.
出处
《中外医疗》
2017年第16期117-119,共3页
China & Foreign Medical Treatment
